Compare Diageo plc (DEO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Novo Nordisk A/S — how do they compare? Diageo plc trades at $93.44 (market cap $53.05B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Diageo plc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| DEO | NVO | |
|---|---|---|
Market Cap | $53.05B | $207.85B |
Sector | Technology | Health |
52-Week High | $115.33 | $63.98 |
52-Week Low | $72.47 | $35.29 |
Enterprise Value | $72.54B | $222.55B |
Dividend Yield | 3.5% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.61, down 3.6% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. A new $1 billion savings plan and focus on spirits and Guinness aim to drive a turnaround, with cash flow from operations strong at $4.4 billion in 2026.
The outlook is cautiously optimistic, with analyst consensus leaning buy (49%) amid execution of the cost-cutting strategy. Risks include North America weakness and competitive pressures, but valuation metrics like P/E of 30.5 reflect growth expectations. The stock offers potential for recovery if management delivers on efficiency gains and market share stabilization.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
